SPRC

Healthcare Biotechnology

SciSparc Ltd.

$4.72

+0.17 +3.74% today

Price History

Not enough data

Key Stats

Market Cap

108.91M

Avg Volume

181,021

P/E (TTM)

0.02

EPS

$248.24

52W High

$43.74

52W Low

$2.98

Div. Yield

0.0%

Valuation

P/B Ratio

0.41

P/S Ratio

95.53

EV/EBITDA

-0.65

EV/Revenue

7.18

Margins

Gross Margin 73.9%

Operating Margin (1720.8%)

Net Margin 0.0%

EBITDA Margin 0.0%

Growth & Returns

Return on Equity

(315.6%)

Return on Assets

(66.9%)

Liquidity & Leverage

Current Ratio

0.87

Quick Ratio

0.79

Debt / Equity

0.24

Total Cash

4.44M

Total Debt

2.68M

About

SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company sells hemp seed oil-based products and others. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and palmitoylethanolamide oral tablets CannAmide in softgel capsule form. It also has an agreement with The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation; and a collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.

scisparc.com